REGENXBIO reports positive interim Phase II data for RGX-314; 71.8% reduction in anti-VEGF injections at 6 months

REGENXBIO Inc.

RGX-314 well tolerated across 50 patients in Cohorts 1-3; no drug-related SAEs.
Cohort 2 (wet AMD) at 6 months: mean BCVA stable (-0.1 letters from Day1); 71.8% reduction in anti-VEGF burden; 40% injection-free.
Cohort 1 (diabetic retinopathy) at 3 months: stable BCVA +2.6 letters vs +0.4 control.
Company plans additional updates; enrollment ongoing in higher-dose cohorts 4/5.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.